Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic disease Akari Therapeutics (AKTX) announces leadership ...
Akari’s lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Akari’s pipeline includes a Phase 3 clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback